New malaria prevention combo tested in mali infants
NCT ID NCT06461026
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the safety of an experimental medicine called L9LS in infants aged 1 to 12 months in Mali. It also looks at how L9LS affects the immune response to a malaria vaccine called R21/Matrix-M. The goal is to find a better way to prevent malaria in young children.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Faladje MRTC Clinic
Faladié, Koulikoro, Mali
-
Kalifabougou MRTC Clinic
Kalifabougou, Koulikoro, Mali
-
Torodo MRTC Clinic
Torodo, Koulikoro, Mali
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill make your blood deadly to malaria mosquitoes?
- Can a new vaccine stop malaria in its tracks?
- Can a new malaria vaccine slash childhood cases? a massive real-world test seeks answers.
- One shot, six months of malaria shield? a new trial tests a powerful antibody in children
- School health rooms and trained teachers: a new hope for Zambia's children?
- Experimental malaria vaccine aims to block parasite growth